Covalon Technologies (OTCMKTS:CVALF) vs. Beta Bionics (NASDAQ:BBNX) Head-To-Head Comparison

Beta Bionics (NASDAQ:BBNX) and Covalon Technologies (OTCMKTS:CVALF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Volatility & Risk

Beta Bionics has a beta of 3.04, indicating that its share price is 204% more volatile than the S&P 500. Comparatively, Covalon Technologies has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Valuation and Earnings

This table compares Beta Bionics and Covalon Technologies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25 million	7.69	-$73.20 million	($1.51)	-11.45
Covalon Technologies	$23.43 million	1.73	$1.47 million	$0.04	36.70

Covalon Technologies has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Covalon Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Beta Bionics and Covalon Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Covalon Technologies	5.05%	5.77%	4.82%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Beta Bionics and Covalon Technologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1	3	6	1	2.64
Covalon Technologies	0	0	0	0	0.00

Beta Bionics presently has a consensus price target of $20.30, suggesting a potential upside of 17.41%. Given Beta Bionics’ stronger consensus rating and higher possible upside, analysts plainly believe Beta Bionics is more favorable than Covalon Technologies.

Summary

Beta Bionics beats Covalon Technologies on 7 of the 13 factors compared between the two stocks.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides wound care dressings; surgical and peri-operative; and infection management products. It offers its products under the Covalon brand name through third-party distribution networks and company’s direct sales force. The company serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians’ offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.